Ascendis Pharma AS (A71) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ascendis Pharma AS (A71) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.72 Million ≈ $-9.03 Million USD) by net assets (€487.97 Million ≈ $570.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see A71 market cap overview for the company's overall valuation and market capitalisation.
Ascendis Pharma AS - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Ascendis Pharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ascendis Pharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascendis Pharma AS ranked by their cash flow conversion efficiency. Explore A71 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
McCormick & Company Incorporated
NYSE:MKC
|
0.050x |
|
Wolters Kluwer N.V.
AS:WKL
|
1.252x |
|
Guardant Health Inc
NASDAQ:GH
|
0.362x |
|
MOL Nyrt.
BUD:MOL
|
0.090x |
|
Ralph Lauren Corp Class A
NYSE:RL
|
0.125x |
|
Lennox International Inc
NYSE:LII
|
0.013x |
|
Bureau Veritas SA
PA:BVI
|
0.133x |
|
Phison Electronics
TWO:8299
|
0.036x |
Annual Cash Flow Conversion Efficiency for Ascendis Pharma AS (2016–2025)
The table below shows the annual cash flow conversion efficiency of Ascendis Pharma AS from 2016 to 2025. View Ascendis Pharma AS stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-162.82 Million ≈ $-190.35 Million |
€53.90 Million ≈ $63.01 Million |
-0.331x | -111.43% |
| 2024-12-31 | €-105.71 Million ≈ $-123.58 Million |
€-306.20 Million ≈ $-357.98 Million |
2.897x | -9.70% |
| 2023-12-31 | €-145.70 Million ≈ $-170.34 Million |
€-467.36 Million ≈ $-546.39 Million |
3.208x | +270.42% |
| 2022-12-31 | €263.35 Million ≈ $307.88 Million |
€-495.70 Million ≈ $-579.52 Million |
-1.882x | -298.24% |
| 2021-12-31 | €883.63 Million ≈ $1.03 Billion |
€-417.65 Million ≈ $-488.28 Million |
-0.473x | -45.98% |
| 2020-12-31 | €838.71 Million ≈ $980.54 Million |
€-271.55 Million ≈ $-317.47 Million |
-0.324x | -9.88% |
| 2019-12-31 | €597.11 Million ≈ $698.09 Million |
€-175.94 Million ≈ $-205.69 Million |
-0.295x | +40.55% |
| 2018-12-31 | €280.05 Million ≈ $327.41 Million |
€-138.80 Million ≈ $-162.27 Million |
-0.496x | +2.43% |
| 2017-12-31 | €187.21 Million ≈ $218.87 Million |
€-95.10 Million ≈ $-111.18 Million |
-0.508x | -49.08% |
| 2016-12-31 | €176.61 Million ≈ $206.48 Million |
€-60.18 Million ≈ $-70.36 Million |
-0.341x | -- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more